Lester A. Dolak

1.8k citations

36 papers · 1.0k indexed · h-index 18

Co-authors: Paul K. Tomich Keith David Watenpaugh Kong-Teck Chong Suvit Thaisrivongs Steve R. Turner Eric P. Seest Musiri N. Janakiraman Joseph W. Strohbach
Topics: Microbial Natural Products and Biosynthesis (7 papers)HIV/AIDS drug development and treatment (7 papers)Chemical Synthesis and Analysis (4 papers)
Cited by: Virology Organic Chemistry Infectious Diseases
Journals: Journal of the American Chemical Society Journal of Medicinal Chemistry Antimicrobial Agents and Chemotherapy
Partner nations: United States

In The Last Decade

Lester A. Dolak

36 papers receiving 952 citations

Peers

Countries citing papers authored by Lester A. Dolak

Since Specialization

Citations

This map shows the geographic impact of Lester A. Dolak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lester A. Dolak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lester A. Dolak more than expected).

Fields of papers citing papers by Lester A. Dolak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lester A. Dolak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lester A. Dolak. The network helps show where Lester A. Dolak may publish in the future.

Co-authorship network of co-authors of Lester A. Dolak

This figure shows the co-authorship network connecting the top 25 collaborators of Lester A. Dolak. A scholar is included among the top collaborators of Lester A. Dolak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lester A. Dolak. Lester A. Dolak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Solvent and in situ catalyst preparation impacts upon Noyori reductions of aryl-chloromethyl ketones: application to syntheses of chiral 2-amino-1-aryl-ethanols 2006 ·Tetrahedron Asymmetry ·Steven P. Tanis,(unknown),James A. Nieman,(unknown),(unknown),(unknown),Paul M. Herrinton,(unknown),(unknown),Lester A. Dolak,(unknown),Eric P. Seest	37
2	The effect of remote chirality on the antibacterial activity of indolinyl, tetrahydroquinolyl and dihydrobenzoxazinyl oxazolidinones 2003 ·Bioorganic & Medicinal Chemistry Letters ·Fred L. Ciske,Michael R. Barbachyn,Michaël Génin,Kevin C. Grega,Chi‐Sing Lee,Lester A. Dolak,Eric P. Seest,William Watt,Wade J. Adams,(unknown),Charles W. Ford,Gary E. Zurenko	22
3	Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition 2001 ·Bioorganic & Medicinal Chemistry Letters ·Atli Thorarensen,(unknown),Douglas C. Rohrer,(unknown),Anthony W. Yem,Vincent D. Marshall,Janet C. Lynn,Michael J. Bohanon,Paul K. Tomich,Gary E. Zurenko,Michael T. Sweeney,Randy Jensen,(unknown),Eric P. Seest,Lester A. Dolak	18
4	Carbon–carbon-linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria 2001 ·Bioorganic & Medicinal Chemistry ·Chi‐Sing Lee,(unknown),Michael R. Barbachyn,Kevin C. Grega,Lester A. Dolak,Charles W. Ford,Randy Jensen,Eric P. Seest,Judith C. Hamel,Ronda D. Schaadt,Douglas Stapert,Betty H. Yagi,Gary E. Zurenko,Michaël Génin	25
5	Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class 1998 ·Journal of Medicinal Chemistry ·Steve R. Turner,Joseph W. Strohbach,Rubén Tommasi,Paul A. Aristoff,Paul D. Johnson,Harvey I. Skulnick,Lester A. Dolak,Eric P. Seest,Paul K. Tomich,Michael J. Bohanon,Miao-Miao Horng,Janet C. Lynn,Kong-Teck Chong,Roger R. Hinshaw,Keith David Watenpaugh,Musiri N. Janakiraman,Suvit Thaisrivongs	215
6	Stereoselective Synthesis of Furo[2,3-c]pyridine Pyrimidine Thioethers, A New Class of Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors 1998 ·The Journal of Organic Chemistry ·Donn G. Wishka,David R. Graber,Eric P. Seest,Lester A. Dolak,Fusen Han,William Watt,Joel Morris	56
7	Asymmetric Syntheses and Absolute Stereochemistry of 5,6-Dihydro-α-pyrones, A New Class of Potent HIV Protease Inhibitors 1997 ·Journal of the American Chemical Society ·Thomas M. Judge,(unknown),Joel Morris,(unknown),(unknown),Geoffrey P. Luke,John Tulinsky,J. M. Tustin,R. Alan Chrusciel,Lester A. Dolak,S. A. MIZSAK,William Watt,James Morris,(unknown),Joseph W. Strohbach,Ronald B. Gammill	34
8	Synthesis and Biological Activities of (R)-5,6-Dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and Its Metabolites 1997 ·Journal of Medicinal Chemistry ·Richard F. Heier,Lester A. Dolak,J. Neil Duncan,Deborah K. Hyslop,Michael F. Lipton,Iain Martin,(unknown),Montford F. Piercey,(unknown),(unknown),Martin Smith,Malcolm W. Moon	63
9	The amphiphilic properties of novenamines determine their activity as inhibitors of HIV-1 RNase H 1996 ·Cellular and Molecular Life Sciences ·Irene W. Althaus,(unknown),(unknown),Ferenc J. Kézdy,(unknown),(unknown),(unknown),Lester A. Dolak,Roger G. Ulrich,Fritz Reusser	9
10	Structure-Based Design of Novel HIV Protease Inhibitors: Sulfonamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Non-Peptidic Inhibitors 1996 ·Journal of Medicinal Chemistry ·Suvit Thaisrivongs,Musiri N. Janakiraman,Kong-Teck Chong,Paul K. Tomich,Lester A. Dolak,Steve R. Turner,Joseph W. Strohbach,Janet C. Lynn,Miao-Miao Horng,Roger R. Hinshaw,Keith David Watenpaugh	79
11	Structure-Based Design of Sulfonamide-Substituted Non-Peptidic HIV Protease Inhibitors 1995 ·Journal of Medicinal Chemistry ·Harvey I. Skulnick,Paul D. Johnson,W. Jeffrey Howe,Paul K. Tomich,(unknown),Keith David Watenpaugh,Musiri N. Janakiraman,Lester A. Dolak,(unknown)	42
12	Structure-Based Design of Novel HIV Protease Inhibitors: Carboxamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Nonpeptidic Inhibitors 1995 ·Journal of Medicinal Chemistry ·Suvit Thaisrivongs,Keith David Watenpaugh,W. Jeffrey Howe,Paul K. Tomich,Lester A. Dolak,Kong-Teck Chong,(unknown),Alfredo G. Tomasselli,Steve R. Turner	103
13	ChemInform Abstract: Structure‐Based Design of Novel HIV Protease Inhibitors: Carboxamide‐ Containing 4‐Hydroxycoumarins and 4‐Hydroxy‐2‐pyrones as Potent Nonpeptidic Inhibitors. 1995 ·ChemInform ·Suvit Thaisrivongs,Keith David Watenpaugh,W. Jeffrey Howe,Paul K. Tomich,Lester A. Dolak,K. T. Chong,C.-S.C. Tomich,A G Tomasselli,(unknown),Joseph W. Strohbach,A. M. Mulichak,Musiri N. Janakiraman,Joseph B. Moon,Janet C. Lynn,Miao-Miao Horng,Roger R. Hinshaw,(unknown),(unknown)	3
14	A novel asymmetric synthesis of atropisomeric 6-aryl pyrazinones via an unusual chirality transfer process. New chiral ligands for the GABAA/Chloride ionophore complex 1995 ·Tetrahedron Letters ·John Tulinsky,S. A. MIZSAK,William Watt,Lester A. Dolak,Thomas M. Judge,Ronald B. Gammill	5
15	Asymmetric Synthesis of an HIV Protease Inhibitor via a Novel .alpha.-Oxoketene/Ketene [4 + 2] Cycloaddition Reaction 1994 ·Journal of the American Chemical Society ·Ronald B. Gammill,Thomas M. Judge,(unknown),Qing‐Wei Zhang,C. Gregory Sowell,B. Vernon Cheney,S. A. MIZSAK,Lester A. Dolak,Eric P. Seest	15
16	Coumarins as inhibitors of bacterial DNA gyrase. 1988 ·The Journal of Antibiotics ·Irene W. Althaus,Lester A. Dolak,Fritz Reusser	18
17	Microbial hydroxylation of novobiocin and related compounds. 1984 ·The Journal of Antibiotics ·Oldrich K. Sebek,Lester A. Dolak	10
18	The synthesis of nitrosofungin, a new antibiotic. 1983 ·The Journal of Antibiotics ·Lester A. Dolak,(unknown)	2
19	The isolation and characterization of the new antibiotic U-60,394. 1980 ·The Journal of Antibiotics ·Lester A. Dolak,(unknown)	3
20	N-Nitroamides and N-Nitrocarbamates. IV. Rates of Decomposition. A Case of Steric Acceleration¹ 1966 ·Journal of the American Chemical Society ·Emil H. White,Lester A. Dolak	19

About Lester A. Dolak

Lester A. Dolak is a scholar working on Organic Chemistry, Toxicology and Applied Microbiology and Biotechnology, having authored 36 papers that have together received 1.0k indexed citations. Recurring topics across this work include Microbial Natural Products and Biosynthesis (7 papers), HIV/AIDS drug development and treatment (7 papers) and Chemical Synthesis and Analysis (4 papers). The work is most often cited by research in Virology (147 citations), Organic Chemistry (572 citations) and Infectious Diseases (219 citations). Lester A. Dolak has collaborated with scholars based in United States. Frequent co-authors include Paul K. Tomich, Keith David Watenpaugh, Kong-Teck Chong, Suvit Thaisrivongs, Steve R. Turner, Eric P. Seest, Musiri N. Janakiraman, Joseph W. Strohbach, Janet C. Lynn and Miao-Miao Horng. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact